KG-1 Xenograft Model Service for AML

The KG-1 cell line, isolated from a patient with acute myeloid leukemia (AML), provides a highly reliable and translationally validated in vivo platform for investigating myeloid malignancies and evaluating the therapeutic efficacy of novel antileukemic drug candidates. As a specialized pre-clinical contract research organization, Alfa Cytology delivers a comprehensive, turnkey KG-1 Xenograft Model Service that seamlessly combines optimized cell handling with standardized in vivo protocols to advance your oncology drug discovery pipeline.

Overview of KG-1 Xenograft Model for AML

The KG-1 xenograft model is an established and highly characterized in vivo translation platform widely deployed in hematological malignancy research, with a particular emphasis on AML. By transplanting human KG-1 myeloblastoid cells into immunodeficient rodent hosts, this model effectively reproduces the systemic dissemination, bone marrow homing kinetics, and peripheral blood pathophysiological profiles observed in clinical leukemia patient populations.

Biologically, the KG-1 model is notable for its dependable engraftment profiles and highly predictable growth rates, which provide researchers with consistent, stable experimental windows for evaluating complex dosing schedules. This model uniquely maintains vital human myeloid molecular signatures, including key cell-surface antigen expressions and distinct intracellular signaling cascades that drive myeloblast expansion. Consequently, the KG-1 model is extensively utilized in pre-clinical screening programs to assess the anti-tumor potency of novel small-molecule inhibitors, targeted monoclonal antibodies, epigenetic modulators, and combination chemoradiotherapy regimens.

Cell Line Information: KG-1

The KG-1 cell line was originally established from the peripheral blood of a patient diagnosed with erythroleukemia that subsequently developed into AML. It exhibits a bone marrow myeloblast morphology under standard in vitro culture conditions and serves as an excellent genetic proxy for hematological oncology research.

Our Services

Workflow of KG-1 Xenograft Model Construction

• Cell Culture & Quality Control: Human KG-1 cells are expanded in vitro using certified growth media under strictly optimized environmental parameters. STR profiling and mycoplasma clearance verification are completed prior to harvesting to guarantee absolute biological purity and phenotypic identity.
• Host Selection & Acclimatization: Healthy, standardized immunocompromised mice (such as NSG or NOD/SCID strains to support hematological engraftment) are sourced from validated vendors. The animals undergo a dedicated acclimatization phase within a controlled facility to establish stable baseline physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability KG-1 cells is prepared in a sterile physiological buffer. The cell mixture is precisely inoculated in vivo into designated rodent cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following successful inoculation, leukemic progression is systematically monitored using FACS to detect human CD45+ or specific myeloid markers in peripheral blood samples. Animal body weights, physical baselines, and general behavioral health are routinely documented.
• Stratification & Dosing: When systemic leukemic burden reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts. This stratification step ensures balanced baseline dimensions across all groups before customized therapeutic dosing regimens commence.

Fig 1. KG-1 Xenograft Model Construction Workflow

Case Study - KG-1 Xenograft Model Development

A pre-clinical validation study was conducted utilizing the KG-1 xenograft model to evaluate the anti-tumor efficacy of a novel targeted small-molecule inhibitor designed for acute myeloid leukemia (AML). Following precision intravenous inoculation of human KG-1 cells into immunodeficient mice, the animals demonstrated steady, systemic leukemic engraftment and a highly predictable disease progression across all study cohorts. Animals assigned to the active treatment group exhibited a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control group, confirming the model's high sensitivity and robust predictive reliability for screening targeted AML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of diverse squamous cell carcinoma lineages, providing reliable in vivo platforms for complex AML studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your AML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing utilizing our KG-1 platform, please reach out to us today to discuss your project layout with our scientific team.

For research use only. Not intended for any clinical use.